Oncorena
Stockholm, SE · 2 known investors
Find your way into Oncorena
106 people in our graph share verified history with the Oncorena team — schools, employers, funds. One of them is your warm intro.
Sylvain Sachotunlockedknows Börje Haraldsson · together at Icahn School of Medicine at Mount Sinai (overlapped)
×11knows the team · via University of Gothenburg
Oncorena is a Swedish pharmaceutical company developing a breakthrough treatment for metastatic renal cancer based on the drug candidate ONC175 (orellanine). The company targets an orphan drug indication with clinical development underway.
Founders & leadership
BH
Börje HaraldssoninResearch leadBörje Haraldsson trained as a nephrologist and holds academic qualifications in medical physics, physiology, and nephrology. He previously served as Global Program Head at Novartis leading international drug development teams, and has held leadership positions in academic and hospital settings.
JN
Jenny NyströminFounder
UN
Ulf Nilsson
LB
Lisa BuvallinFounder
PF
Pål FalckinFounder
SD
Susanna DahlgreninChief Operating Officer
HX
Hanjing XieinFounder
AS
Ann-Kristin SpiikinFounder
CL
Christer Lundell-Ek
ÅH
Åsa HolmgrenHead of Regulatory Affairs
Investors · 2
Frequently asked questions
- What does Oncorena do?
- Oncorena is a Swedish pharmaceutical company developing a breakthrough treatment for metastatic renal cancer based on the drug candidate ONC175 (orellanine). The company targets an orphan drug indication with clinical development underway.
- Who founded Oncorena?
- Oncorena was founded by Börje Haraldsson, Jenny Nyström, Ulf Nilsson, Lisa Buvall.
- Who are Oncorena's investors?
- Oncorena's investors include HealthCap, FSG.
- Where is Oncorena headquartered?
- Oncorena is headquartered in Stockholm, SE.